文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性抗VEGF治疗12年生存分析洞察

Insights From Survival Analyses During 12 Years of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

该回顾性队列研究纳入7802只接受抗VEGF治疗的新生血管性AMD眼,使用Kaplan-Meier和Cox模型分析视力结局。首次注射后达到ETDRS字母评分≥70(20/40)的中位时间为2.0年,达到该结局的患者中位维持时间为1.1年。

要点

  • 首次抗VEGF注射后达到视力≥20/40的中位时间为2.0年。
  • 达到视力≥20/40的患者中位维持时间为1.1年。
  • 基线视力、年龄和注射次数是视力结局的预测因素。

核心结论

  • 新生血管性AMD患者开始抗VEGF治疗后,更可能在治疗前2.0年内获得积极视力结局,通常维持1.1年,但随后在8.7年内恶化至差视力。

研究设计与样本

  • 回顾性队列研究,覆盖三级眼科中心12年观察期,纳入7802只治疗初治的新生血管性AMD眼,接受雷珠单抗或阿柏西普治疗。

主要发现

  • 达到ETDRS字母评分≥70(20/40)的中位时间为首次抗VEGF注射后2.0年(95%CI 1.87-2.32)。
  • 达到该结局的4439/7802例患者(57%)中,中位维持时间为1.1年(95%CI 1.1-1.2)。
  • 预测因素包括基线视力(每5个ETDRS字母或1行,HR 1.43;95%CI 1.40-1.46)、基线年龄(每5岁,HR 0.88;95%CI 0.86-0.90)和注射次数(HR 1.12;95%CI 1.10-1.15)。

临床怎么用

  • 生存分析技术可用于回顾性临床实践视力结局,为新生血管性AMD患者提供长期预后信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although multiple imputation models for missing data and the use of mixed-effects models generally provide better outcome estimates than using only observed data or last observation carried forward in clinical trials, such approaches usually cannot be applied to visual outcomes from retrospective analyses of clinical practice settings, also called real-world outcomes. OBJECTIVE: To explore the potential usefulness of survival analysis techniques for retrospective clinical practice visual outcomes. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study covered a 12-year observation period at a tertiary eye center. Of 10 744 eyes with neovascular age-related macular degeneration receiving anti-vascular endothelial growth factor (VEGF) therapy between October 28, 2008, and February 1, 2020, 7802 eyes met study criteria (treatment-naive, first-treated eyes starting anti-VEGF therapy). Eyes were excluded from the analysis if they received photodynamic therapy or macular laser, any previous anti-VEGF therapy, treatment with anti-VEGF agents other than ranibizumab or aflibercept, or had an unknown date or visual acuity (VA) value at first injection. MAIN OUTCOMES AND MEASURES: Kaplan-Meier estimates and Cox proportional hazards modeling were used to consider VA reaching an Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 70 (Snellen equivalent, 20/40) or better, duration of VA sustained at or better than 70 (20/40), and VA declining to 35 (20/200) or worse. RESULTS: A total of 7802 patients (mean [SD] age, 78.7 [8.8] years; 4776 women [61.2%]; and 4785 White [61.3%]) were included in the study. The median time to attaining a VA letter score greater than or equal to 70 (20/40) was 2.0 years (95% CI, 1.87-2.32) after the first anti-VEGF injection. Predictive features were baseline VA (hazard ratio [HR], 1.43 per 5 ETDRS letter score or 1 line; 95% CI, 1.40-1.46), baseline age (HR, 0.88 per 5 years; 95% CI, 0.86-0.90), and injection number (HR, 1.12; 95% CI, 1.10-1.15). Of the 4439 of 7802 patients (57%) attaining this outcome, median time sustained at an ETDRS letter score of 70 (20/40) or better was 1.1 years (95% CI, 1.1-1.2). CONCLUSIONS AND RELEVANCE: In this cohort study, patients with neovascular age-related macular degeneration beginning anti-VEGF therapy were more likely to experience positive visual outcomes within the first 2.0 years after treatment, typically maintaining this outcome for 1.1 years but then deteriorating to poor vision within 8.7 years. These findings demonstrate the potential usefulness of the proposed analyses. This data set, combined with the statistical approach for retrospective analyses, may provide long-term prognostic information for patients newly diagnosed with this condition.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Fu DJ, Keenan TD, Faes L, et al. Insights From Survival Analyses During 12 Years of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2021. PMID: 33211064. doi:10.1001/jamaophthalmol.2020.5044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。